crystal structure of BCL-2 G101V mutation with venetoclax

4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl )methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
Venetoclax, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)pipe razin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Apoptosis regulator Bcl-2,Bcl-2-like protein 1,Apoptosis regulator Bcl-2

MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDDVEENRTEAPEGTESEVVHLTLRQAVDDFSRRYRRDFAEMSSQLHL
TPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVEL
YGPSMR

Authors state that the data were processed and refined in spacegroup P21, despite being possible to merge and refine in orthorhombic spacegroup P212121. This was due to poorer refinement statistics in the orthorhombic spacegroup.

BCL-2, Venetoclax, complex, Protein-protein interface inhibitor, resistance mutation, FDA approved drug complex, APOPTOSIS

VVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVD
NIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMR